# Pluvicto Real-world Investigation in Survival in Metastatic CRPC

> **NCT07697989** · — · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 1085 (estimated)

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant
- Neoplasm Metastasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07697989
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-15
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 1085 (ESTIMATED)
- **Last updated:** 2026-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07697989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07697989, "Pluvicto Real-world Investigation in Survival in Metastatic CRPC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07697989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*